Article

Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibition

2024-02-13

Abstract excerpt

<title>Abstract</title> <p>Understanding mechanisms of resistance to PARP inhibitors (PARPi) represents a clinically relevant goal that is addressed in this study using a novel methodology. A framework has been developed formulating a mathematical model accounting for intrinsic resistance to the PARPi olaparib, identified by fitting the model to tumour growth metrics from breast cancer patient-derived xenograft (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 93bc9430-f1d6-56c2-988d-856a36b75545
DOI: 10.21203/rs.3.rs-3893834/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibitionDOI 10.21203/rs.3.rs-3893834/v1Read

Machine learning-based prediction of response to PARP inhibition across cancer typesSemantic proximity Read

Machine learning models to predict <i>in vivo</i> drug response via optimal dimensionality reduction of tumour molecular profilesSemantic proximity Read

Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case studySemantic proximity Read

A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitorsSemantic proximity Read

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibSemantic proximity Read

Investigating mechanisms of acquired drug resistance in Triple Negative Breast CancerSemantic proximity Read

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity Read

Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXsSemantic proximity Read

A Theoretical Framework for Quantifying Tumour Resistance to Standardized Treatments: A Novel Rudimentary Scalar Mathematical Model with Implications for Breast Cancer Prognosis and TreatmentSemantic proximity Read

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancerSemantic proximity Read

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesSemantic proximity Read

Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitorsSemantic proximity Read